Polymorphisms in the promotor region of theCRBNgene as a predictive factor for peripheral neuropathy in the course of thalidomide‐based chemotherapy in multiple myeloma patients-Reference-Cited by-同舟云学术

Polymorphisms in the promotor region of theCRBNgene as a predictive factor for peripheral neuropathy in the course of thalidomide‐based chemotherapy in multiple myeloma patients

Published:2019-05-22 Issue:5 Volume:186 Page:695-705
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Mlak Radosław¹^ORCID,Szudy‐Szczyrek Aneta²^ORCID,Mazurek Marcin¹,Szczyrek Michał³,Homa‐Mlak Iwona¹,Mielnik Michał²,Chocholska Sylwia²,Jankowska‐Łęcka Olga²,Małecka‐Massalska Teresa¹,Hus Marek²

Affiliation:

1. Department of Human Physiology Medical University of Lublin Lublin Poland

2. Department of Haemato‐oncology and Bone Marrow Transplantation Medical University of Lublin Lublin Poland

3. Department of Pneumonology, Oncology and Allergology Medical University of Lublin Lublin Poland

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15972

Reference49 articles.

1. Association Study of Selected Genetic Polymorphisms and Occurrence of Venous Thromboembolism in Patients With Multiple Myeloma Who Were Treated With Thalidomide